Key facts
- BC3 Technologies’s last known valuation is $40.5M (Nov 2025).
- It has raised $5.9M across 2 recorded rounds; the latest was Seed Round ($1.0M) in Nov 2025.
- Notable investors include Astralabs, Quake Capital.
- BC3 Technologies has filed 1 Form D with the SEC, most recently Jun 2024 ($2.7M sold to 17 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BC3 Technologies
Funding rounds
2 roundsAbout BC3 Technologies
Developer of proprietary chitosan-based aerosolised hemostatic products intended to stop bleeding. The company's product features powerful anti-hemorrhagic and anti-microbial properties that will make wounds stop bleeding effectively, greatly increase infection resistance, and prevent the growth of harmful bacteria, enabling police, first responders, other medical professionals, and the military to treat life-threatening bleeding.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2018
- Employees
- 4
- Website
- bc3tech.com/
- Ownership
- Privately Held (backing)
BC3 Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BC3 Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BC3 Technologies in its N-PORT filings yet. We sweep new filings monthly.